생명과학회지 (Journal of Life Science)

  • 제29권11호
  • /
  • Pages.1267-1272
  • /
  • 2019
  • /
  • 1225-9918(pISSN)
  • /
  • 2287-3406(eISSN)
한국생명과학회 (Korean Society of Life Science)
권호 표지
DOI QR코드

DOI QR Code

부산지역 여성의 고위험군 인유두종 바이러스 유병률과 유전자형 분석

Prevalence and Genotype Analysis of High Risk-human Papillomavirus Infection in Busan Women

  • 강창수 (부산의료원 병리과) ;
  • 이경은 (부산가톨릭대학교 임상병리학과)
  • Kang, Chang-Soo (Department of Pathology, Busan Medical Center) ;
  • Lee, Kyung Eun (Department of Clinical Laboratory Science, Catholic University of Pusan)
  • 투고 : 2019.10.12
  • 심사 : 2019.10.24
  • 발행 : 2019.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

자궁경부암의 주요 원인은 인유두종 바이러스(HPV)로 알려져 있으며, 자궁경부암 환자의 99.7%에서 HPV DNA가 검출된다고 하였다. 또한 세계적으로 HPV 16 및 18의 유병률이 가장 높은 것으로 보고되고 있으나, 한국을 포함한 아시아에서는 HPV 52 및 58의 유병률이 더 높게 나타나고 있다. 따라서 본 연구에서는 부산지역 여성의 HPV 유병률과 고위험군 인유두종 바이러스(HR-HPV) 유전자형을 분석하여 자궁경부암 예방을 위한 기초 자료를 확보하고자 하였다. 2016년 1월부터 2017년 12월까지 부산 산부인과병원을 내원한 여성 중 HPV 유전자형 검사를 시행한 여성 1,995예를 대상으로 분석하였다. 본 연구에서는 부산지역 여성에서 28.3%(565/1995)의 HPV 유병률을 확인하였다. 특히 HR-HPV 감염률은 75.4%(426/565)로 높게 나타났으며, HR-HPV 유전자형은 52형(63/565, 11.2%)이 가장 높게 나타났고, 그 다음으로 58형(56/565, 9.9%), 53형(55/565. 9.7%), 16형(53/565, 9.4%) 순으로 나타났다. 또한 18~39세이하의 젊은 여성들의 HR-HPV 감염률이 60.3%(257/426)로 높게 나타나므로 지속적인 감시가 필요할 것으로 사료된다. 또한 세포학적 결과에서 자궁경부내 상피의 이상소견이 높아지는 HSIL과 SCC에서 HPV 16형이 높은 감염률을 보였으나, 향후 더 많은 검체를 이용하여 자궁경부내 종양 발생과 관련된 HR-HPV 유전자형을 확인해야 될 것으로 사료된다.

The main cause of cervical cancer is the human papillomavirus (HPV), and HPV DNA has been reported in 99.7% of patients with cervical cancer. The worldwide prevalence is highest for the HPV 16 and 18 genotypes, but HPV 52 and 58 have the highest prevalence in Asian countries, including Korea. The purpose of this study was to obtain basic data for the prevention of cervical cancer by analyzing the prevalence of HPV and the genotypes of high risk-human papillomavirus (HR-HPV) infection in women in Busan, Korea. We analyzed 1,995 cases of HPV in women who visited a Busan obstetrics and gynecology hospital from January 2016 to December 2017. The prevalence of HPV among these women was 28.3% (565/1995), and the HR-HPV infection rate was 75.4% (426/565). The HR-HPV genotype with the highest prevalence was HPV-52 (63/565, 11.2%), followed by HPV-58 (56/565, 9.9%), HPV-53 (55/565, 9.7%), and HPV-16 (53/565, 9.4%). The HR-HPV infection rate of young women 18-39 years old was 60.3% (257/426), so this age group should undergo continuous monitoring. The cytological results revealed a high infection rate for HPV-16 in high grade squamous intraepithelial lesions (HSIL) and squamous cell carcinoma (SCC). However, further evaluation of more samples is needed to confirm the HR-HPV genotypes related to the development of cervical epithelial neoplasias.

키워드

참고문헌

  1. Bernard, H. U., Chan, S. Y., Manos, M. M., Ong, C. K., Villa, L. L., Delius, H., Peyton, C. L., Bauer, H. M. and Wheeler, C. M. 1994. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence and phylogenetic algorithms. J. Infect. Dis. 170, 1077-1085. https://doi.org/10.1093/infdis/170.5.1077
  2. Bosch, F. X., Burchell, A. N., Schiffman, M., Giuliano, A. R., de Sanjose, S., Bruni, L., Tortolero-Luna, G., Kjaer, S. K. and Munoz, N. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in Cervical Neoplasia. Vaccine 10, 1-16.
  3. Castle, P. E. 2004. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J. Low. Genit Tract. Dis. 8, 224-230. https://doi.org/10.1097/00128360-200407000-00011
  4. Chan, K. S., Li, W. H., Chan, Y. M., Ma, W. L., Cheung, J. L. and Cheng, A. F. 1999. High prevalence of human papillomavirus type 58 in china women with cervical cancer and precancerous lesion. J. Med. Virol. 59, 232-238. https://doi.org/10.1002/(SICI)1096-9071(199910)59:2<232::AID-JMV18>3.0.CO;2-7
  5. Clifford, G. M., Gallus, S., Herrero, R., Munoz, N., Snijders, P. J., Vaccarella, S., Anh, P. T., Ferreccio, C., Hieu, N. T., Matos, E., Molano, M., Rajkumar, R., Ronco, G., de Sanjose, S., Shin, H. R., Sukvirach, S., Thomas, J. O., Tunsakul, S., Meijer, C. J. and Franceschi, S. 2005. IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366, 991-998. https://doi.org/10.1016/S0140-6736(05)67069-9
  6. Cubie, H.A. 2013. Diseases associated with human papillomavirus infection. Virology 445, 21-34. https://doi.org/10.1016/j.virol.2013.06.007
  7. De Sanjose, S., Diaz, M., Castellsague, X., Clifford, G., Bruni, L., Munoz, N. and Bosch, F. X. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7, 453-459. https://doi.org/10.1016/S1473-3099(07)70158-5
  8. Herrero, R., Hildesheim, A., Bratti, C., Sherman, M. E., Hutchinson, M., Morales, J., Balmaceda, I., Greenberg, M. D., Alfaro, M., Burk, R. D., Wacholder, S., Plummer, M. and Schiffman, M. 2000. Population-based study of human papillomavirus infection and cervical neoplasia in Rural Costa Rica. J. Natl. Cancer inst. 92, 464-473. https://doi.org/10.1093/jnci/92.6.464
  9. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J. and Burk, R. D. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338, 423-428. https://doi.org/10.1056/NEJM199802123380703
  10. Hwang, H. S., Park, M., Lee, S. Y., Kwon, K. H. and Pang, M. G. 2004. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol. Biomarkers Prev. 13, 2153-2156.
  11. Jung, K. W., Won, Y. J., Kong, H. J., Lee, E. S. and The Community of Population-Based Regional Cancer Registries. 2018. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Res. Treat. 50, 303-316. https://doi.org/10.4143/crt.2018.143
  12. Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D. and Kiviat, N. B. 1992. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327, 1272-1278. https://doi.org/10.1056/NEJM199210293271804
  13. Lee, D. S., Kim, S. H., Park, S. J., Kim, T. U., Jin, H. W., Park, K. H. and Lee, H. Y. 2011. Human papillomavirus prevalence in gangwon province using reverse blot hybridization assay. Kor. J. Pathol. 45, 348-353. https://doi.org/10.4132/KoreanJPathol.2011.45.4.348
  14. Lee, J. K. 2006. HPV DNA test as a Diagnostic tool for cervical cancer. Obstet. Gynecol. Sci. 49, 261-275.
  15. Myers, E. R., McCrory, D. C., Nanda, K., Bastian, L. and Matchar, D. B. 2000. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol. 151, 1158-1171. https://doi.org/10.1093/oxfordjournals.aje.a010166
  16. Malagon, T., Drolet, M., Boily, M. C., Franco, E. L., Jit, M., Brisson, J. and Brisson, M. 2012. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 781-789. https://doi.org/10.1016/S1473-3099(12)70187-1
  17. Min, K. J., Kwon, S. H., Kim, S. H., Kim, H. J., Seong, S. J., Song, Y. J., Shin, J. W., Lee, K. H., Lim, M. C., Chung, H. H., Ju, W., Hong, J. H., Kim, J. W., Bae, D. S. and Lee, J. K. 2016. Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline. J. Gynecol. Oncol. 27, 1-14. https://doi.org/10.3802/jgo.2016.27.e1
  18. Nah, E. H., Cho, S., Kim, S. Y. and Cho, H. I. 2017. Human papillomavirus genotype fistribution among 18,815 Women in 13 Korean cities and relationship with cervical cytology findings. Ann. Lab. Med. 37, 426-433. https://doi.org/10.3343/alm.2017.37.5.426
  19. Ostor, A. G. 1993. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12, 186-192. https://doi.org/10.1097/00004347-199304000-00018
  20. Ouh, Y. T., Min, K. J., Cho, H. W., Ki, M., Oh, J. K., Shin, S. Y., Hong, J. H. and Lee, J. K. 2018. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016. J. Gynecol. Oncol. 29, 1-10. https://doi.org/10.3802/jgo.2018.29.e1
  21. Pinto, A. P. and Crum, C. P. 2000. Natural history of cervical neoplasia: defining progression and its consequence. Clin. Obstet. Gynecol. 43, 352-362. https://doi.org/10.1097/00003081-200006000-00015
  22. Richart, R. M. and Barron, B. A. 1969. A follow-up study of patients with cervical dysplasia. Am. J. Obstet. Gynecol. 105, 386-393. https://doi.org/10.1016/0002-9378(69)90268-3
  23. Soto-De, L. S., Camargo, M., Sanchez, R., Munoz, M., Perez-Prados, A., Purroy, A., Patarroyo, M. E. and Patarroyo, M. A. 2011. Disribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors. PLoS One 6, e14705. https://doi.org/10.1371/journal.pone.0014705
  24. Sasagawa, T., Basha, W., Yamazaki, H. and Inoue, M. 2001. High risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol. Biomarkers Prev. 10, 45-52.
  25. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J. and Munoz, N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  26. WHO. 2014. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly. Epidemiol. Rec. 89, 465-491.